“Thermal Liquid Biopsy (BLT): Clinical application of serum calorimetric curve analysis as a new method of diagnosis and follow-up of tumor digestive pathology” (Q3167697): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claim: summary (P836): Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 p...)
(‎Created claim: summary (P836): Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 par...)
Property / summary
 
Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 parameters were obtained that showed sensitivity and specificity values between 75-90 %. This project aims to make a decisive leap towards the clinical implementation of the serum BLT test in digestive pathologies of a tumor character. To this end, the application and evaluation of the test is proposed in the diagnosis and follow-up of patients within the hospital digestive service, as well as the isolation and identification of those disease-specific tumor biomarkers, who are responsible for changes in the serum BLT thermogram and that lead to the detection of pathology. For this purpose: 1/A diagnostic validation study of the technique will be carried out with 1000 patients included in the colon screening program and the results of the BLT test will be contrasted with two reference tests: Hidden Blood in Feces and Colonoscopy; 2/The serum of patients (monitoring in consultation) who have digestive pathologies already diagnosed with risk of malignancy towards tumor disease will be analysed by BLT; 3/The current nanotechnological tools will be used, such as dendrimer-based structures, such as Pluronic® F-127 derivatives, capable of specific binding to plasma proteins. BLT could be implanted at a clinical level, not only as a diagnostic or stratification technique of patients, but as a monitoring or follow-up system during therapeutic treatment. (English)
Property / summary: Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 parameters were obtained that showed sensitivity and specificity values between 75-90 %. This project aims to make a decisive leap towards the clinical implementation of the serum BLT test in digestive pathologies of a tumor character. To this end, the application and evaluation of the test is proposed in the diagnosis and follow-up of patients within the hospital digestive service, as well as the isolation and identification of those disease-specific tumor biomarkers, who are responsible for changes in the serum BLT thermogram and that lead to the detection of pathology. For this purpose: 1/A diagnostic validation study of the technique will be carried out with 1000 patients included in the colon screening program and the results of the BLT test will be contrasted with two reference tests: Hidden Blood in Feces and Colonoscopy; 2/The serum of patients (monitoring in consultation) who have digestive pathologies already diagnosed with risk of malignancy towards tumor disease will be analysed by BLT; 3/The current nanotechnological tools will be used, such as dendrimer-based structures, such as Pluronic® F-127 derivatives, capable of specific binding to plasma proteins. BLT could be implanted at a clinical level, not only as a diagnostic or stratification technique of patients, but as a monitoring or follow-up system during therapeutic treatment. (English) / rank
 
Normal rank
Property / summary: Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 parameters were obtained that showed sensitivity and specificity values between 75-90 %. This project aims to make a decisive leap towards the clinical implementation of the serum BLT test in digestive pathologies of a tumor character. To this end, the application and evaluation of the test is proposed in the diagnosis and follow-up of patients within the hospital digestive service, as well as the isolation and identification of those disease-specific tumor biomarkers, who are responsible for changes in the serum BLT thermogram and that lead to the detection of pathology. For this purpose: 1/A diagnostic validation study of the technique will be carried out with 1000 patients included in the colon screening program and the results of the BLT test will be contrasted with two reference tests: Hidden Blood in Feces and Colonoscopy; 2/The serum of patients (monitoring in consultation) who have digestive pathologies already diagnosed with risk of malignancy towards tumor disease will be analysed by BLT; 3/The current nanotechnological tools will be used, such as dendrimer-based structures, such as Pluronic® F-127 derivatives, capable of specific binding to plasma proteins. BLT could be implanted at a clinical level, not only as a diagnostic or stratification technique of patients, but as a monitoring or follow-up system during therapeutic treatment. (English) / qualifier
 
point in time: 12 October 2021
Timestamp+2021-10-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 17:33, 12 October 2021

Project Q3167697 in Spain
Language Label Description Also known as
English
“Thermal Liquid Biopsy (BLT): Clinical application of serum calorimetric curve analysis as a new method of diagnosis and follow-up of tumor digestive pathology”
Project Q3167697 in Spain

    Statements

    0 references
    82,875.0 Euro
    0 references
    165,750.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2019
    0 references
    31 March 2022
    0 references
    INSTITUTO DE INVESTIGACION SANITARIA ARAGON
    0 references

    41°39'7.67"N, 0°52'51.38"W
    0 references
    50297
    0 references
    La Biopsia Líquida Térmica (BLT) es un término acuñado por nuestro grupo recientemente para hacer referencia al análisis del suero de un individuo mediante la técnica calorimetría diferencial de barrido (DSC). Nuestros estudios previos han contribuido a su desarrollo, estando más cerca de su utilización en clínica en el contexto del cribado de un proceso tumoral determinado y en la monitorización del avance/control de la enfermedad. Por ejemplo, tras analizar las curvas de BLT de pacientes con adenocarcinoma ductal de páncreas (PDAC) se obtuvieron 18 parámetros que mostraron valores de sensibilidad y especificidad entre 75-90%. En este proyecto se propone dar un salto decisivo hacia la implementación clínica del test BLT de suero en patologías digestivas de carácter tumoral y para ello se plantea la aplicación y evaluación del test en el diagnóstico y seguimiento de pacientes dentro del servicio de digestivo del hospital, así como el aislamiento y la identificación de aquellos biomarcadores tumorales específicos de enfermedad, que son los responsables de los cambios en el termograma BLT del suero y que conducen a la detección de patología. Para ello: 1/Se realizará un estudio de validación diagnóstica de la técnica con 1000 pacientes incluidos en el programa de cribado de colon y se contrastarán los resultados del test BLT con dos pruebas referencia: Sangre Oculta en Heces y Colonoscopia; 2/Se analizará por BLT el suero de aquellos pacientes (seguimiento en consulta) que tengan patologías digestivas ya diagnosticadas con riesgo de malignización hacia enfermedad tumoral; 3/Se utilizarán herramientas actuales nanotecnológicas, como son estructuras basadas en dendrímeros, como los derivados de Pluronic® F-127, capaces de unirse a proteínas del plasma de forma específica. BLT podría implantarse a nivel clínico, no sólo como técnica diagnóstica o de estratificación de pacientes, sino como sistema de monitorización o seguimiento durante el tratamiento terapéutico. (Spanish)
    0 references
    Thermal Liquid Biopsy (BLT) is a term coined by our group recently to refer to an individual’s serum analysis using differential scanning calorimetry (DSC). Our previous studies have contributed to its development, being closer to clinical use in the context of screening a given tumor process and in monitoring disease progression/control. For example, after analysing the BLT curves of patients with ductal pancreatic adenocarcinoma (PDAC), 18 parameters were obtained that showed sensitivity and specificity values between 75-90 %. This project aims to make a decisive leap towards the clinical implementation of the serum BLT test in digestive pathologies of a tumor character. To this end, the application and evaluation of the test is proposed in the diagnosis and follow-up of patients within the hospital digestive service, as well as the isolation and identification of those disease-specific tumor biomarkers, who are responsible for changes in the serum BLT thermogram and that lead to the detection of pathology. For this purpose: 1/A diagnostic validation study of the technique will be carried out with 1000 patients included in the colon screening program and the results of the BLT test will be contrasted with two reference tests: Hidden Blood in Feces and Colonoscopy; 2/The serum of patients (monitoring in consultation) who have digestive pathologies already diagnosed with risk of malignancy towards tumor disease will be analysed by BLT; 3/The current nanotechnological tools will be used, such as dendrimer-based structures, such as Pluronic® F-127 derivatives, capable of specific binding to plasma proteins. BLT could be implanted at a clinical level, not only as a diagnostic or stratification technique of patients, but as a monitoring or follow-up system during therapeutic treatment. (English)
    12 October 2021
    0 references
    Zaragoza
    0 references

    Identifiers

    PI18_00349
    0 references